psalexa
SearchBar Icon

Promising Targets Spur the Growth of IgA Nephropathy Therapeutics Pipeline

Published Date:   March 2018

The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the period 2016 – 2025.

Browse report overview with detailed TOC on "Immunoglobulin A (IgA) Nephropathy Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations, Patient Size, and Epidemiology Forecast to 2025" at:https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis

Insights on Pipeline Segments

The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration.

Positive Clinical Trial Results Propelling the IgA Nephropathy Pipeline Growth

The drugs candidates that are being developed by the different pharmaceutical companies have demonstrated positive clinical trial results which in-turn increase their further development. For instance, in May 2017 OMS721, a drug candidate developed by the Omeros Corporation demonstrated positive clinical trial results in the treatment of patients with IgA nephropathy. In December 2016, Anthera Pharmaceuticals, Inc. presented positive clinical trial results of blisibimod in 48-week, Phase II study in the treatment of patients with IgA nephropathy.

Promising Targets Spur the IgA Nephropathy Pipeline Growth

Companies are developing drugs with promising targets for the treatment of the disease. The potential targets may possibly stop or slow the progression of the disease with better efficacy and less side effects. Potential targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS), melanocortin receptors, and NF-κB signaling can also prove to be effective in IgA nephropathy treatment, since clinical trials of drug candidates meant to act on these targets have shown promising results. This is encouraging companies to further invest in their pipeline to develop drugs acting on new targets, thereby, fueling the growth of the pipeline.

Technological Advancements at Cellular and Molecular Level Strengthening the IgA Nephropathy Pipeline

Various new technologies are being used by the companies for the development of drugs to treat IgA nephropathy. For instance, TARGIT drug delivery technology is being used by Calliditas Therapeutics AB for the development of novel drug therapies.
Some of the key players developing drugs for the treatment of IgA nephropathy include Mallinckrodt plc, Merck KGaA, Novartis AG, and Shire plc.

IgA Nephropathy Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company